首页> Vaccine> Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.

导出 OA

翻译打印收藏纠错

第一作者： Sofiya,Fedosyuk

第一单位： Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.

作者： Sofiya,Fedosyuk ^[1] ; Thomas,Merritt ^[2] ; Marco Polo,Peralta-Alvarez ^[1] ; Susan J,Morris ^[1] ; Ada,Lam ^[3] ; Nicolas,Laroudie ^[4] ; Anilkumar,Kangokar ^[3] ; Daniel,Wright ^[1] ; George M,Warimwe ^[5] ; Phillip,Angell-Manning ^[2] ; Adam J,Ritchie ^[1] ; Sarah C,Gilbert ^[1] ; Alex,Xenopoulos ^[6] ; Anissa,Boumlic ^[4] ; Alexander D,Douglas ^[7]

作者单位： Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK. ^[1] Clinical Biomanufacturing Facility, University of Oxford, Roosevelt Drive, Oxford OX3 7JT, UK. ^[2] Millipore (UK) Ltd. Bedfont Cross, Stanwell Road, TW14 8NX Feltham, UK. ^[3] Millipore SAS, 39 Route Industrielle de la Hardt, Molsheim 67120, France. ^[4] Centre for Tropical Medicine and Global Health, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK; KEMRI-Wellcome Trust Research Programme, P.O. 230-80108 Kilifi, Kenya. ^[5] EMD Millipore Corporation, 80 Ashby Road, Bedford, MA 01730, USA. ^[6] Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK. Electronic address: sandy.douglas@ndm.ox.ac.uk. ^[7]

关键词 Biomanufacturing Bioreactor Clinical trials GMP Purification Simian adenovirus Single-use